Login to Your Account



AMERICAN ASSOCIATION FOR CANCER RESEARCH 2017

PARP inhibitors to be tested in IDH-mutated tumors in Yale study

By Anette Breindl
Senior Science Editor

Tuesday, April 4, 2017

WASHINGTON – Researchers at Yale University have received conditional approval for a clinical trial that will test whether isocitrate dehydrogenase (IDH)-mutated tumors might respond better to poly-ADP ribose polymerase (PARP) inhibitors than to IDH inhibitors.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription